ba407 2 ,
.

,
.
,

. ,
.

, .
,
.
,
.
,
.
, ,


, ,
,
,
.
1. ·······························································1
. ······················································································1
. ·························································································3
1. / ·······························································9
. ·······················································································9
. ······························································································11
. - ······················································································14
2. ········································································18
. ······························································································25
1. ···························································································27
. ·····································································································27
. ·········································································································28
2. ············································46
3. ··········································································49
5 ···········································································53
························································································57
< 2-1> - ··········································16
< 2-2> ···························································17
< 2-3> C ·······18
< 2-4> ········································23
< 2-5> ···································································26
< 3-1> ·················································30
< 3-2> ·················································36
< 4-1> 2001 ··········································································43
< 4-2> 2001 5 · ···························44
< 4-3> ·· ············································45
< 4-4> ·····················································································48

< 2-2> ·······················································13
< 2-3> ·················································14
< 2-4> C ···························19
< 2-5> SOU ···························································20
< 2-6> SOU ···························································20
< 3-1> ·····································27
< 3-2> ····················································28
< 3-3> CNS ································································32
< 3-4> CNS ···················32
< 3-5> ···········································35
iv
< 3-7> ··················································39
< 4-1> · ···············································47
1 1
(< 1-1> ).
< 1-1>
Ischemia Brain(stroke)
Systemic(cardiac arrest)
Traumatic brain injury
Epilepsy
: Butler, T.L., Kassed, C.A and Pennypacker, K.R., “Signal Transduction and
Neurosurvival in Experimental Models of Brain Injury”, 59(5), Brain
Research Bulletin, 2003, p.340, Table 1 .
2 ()
,
80% .
- , ,
.
- ,
.
,

.
.
.

, ,
.
-
,
1 3
,
.
( ),
()
.
( )
, .
- ,
, .
.
,
.

.
- ( )
,
.
4 ()

.
-

.
,

, ( ,
30% ).
( ; Dipyridamole), (Ticlopidine),
(Clopidogrel), (Warfarin), ,
.
- t-PA
( FDA ).
.
.
.
- (Carotid Endarterectomy)
(Angioplasty) .
- .
(Acetylchlin Esterase
(Janssen) Reminyl ,
Tacrine Aricept(Donepezil)
.
- RS-86, ,
Nefiracetam, Lily Xanomeline FDA
.
- 1 (Carbamazepine)
(Phenytoin) , (Valproic acid)
, ,
.
.
- , COMT
, (Anticholinergics), (Antiviral
2.
” .
“2 ”
.
- -
1 7
Mapping) , IPC
C .
“3 ” (KISTI)
, ,
··
.
.

, ( ),
, / .


.
- ,
,
.
,
.

, (, 2003), KDD(Knowledge Discovery
in Database)/KM(Knowledge Mapping), Bibliometrics

.
DB , Bibliometrics, Text
mining, Mapping
KDD(Porter, 2004; , 2004, Yoon
and Park, 2005; , 2005; NISTEP, 2003).
, “ ” ,

100% .
- ,
( )
.
,
.
, KDD/KM
,
2 11
.
.
,
- .
- IT 15
, - -
- 15 .
.

, (<
2-1> ).
1) , , , / ,
“ ” /
.
12 ()


• • •
IT 15
.
.
< 2-2> 1)
, 2) , 3) 3 10
.2)
2 13
1:

- : , ,
,
- : , ,
.
), ( , ),
( , , )
(< 2-3> ).
14 ()

• –
,
DB
.
.
/
2 15
/
, /
.
- , “
/ / ”3)
.
.
< 2-1>
.4)
.
3) ,
.
4) , , “-
,” , 8(2), 2005, 863-887.
16 ()





* : 1972 1995 30
IPC
(Industry of Manufacture : IOM) (Sector of
Use : SOU) . Yale IPC
IOM-SOU , IPC
IOU-SOU
(Johnson, 2002).
: , , “-
,” , 8(2), 2005, p.873.
2 17
(),


, .
- DB (
, 2004; , 2005)
(< 2-2> ).


100 ~


5)

.
IPC C
, 19902001
(<
2-3>, < 2-4> ).
< 2-3> C

IPC
, , ,


.
C12H

.
2 19
- 19902000
10 48% ,

S/W KITAS TM
(100)
,
.
. : SOU
OTC
(126 ISIC ) ,
20 ()
< 2-5> SOU
0
1 2 0 0 0
1 6 0 0 0
1 1 0 1 9 2 8 3 7 4 6 5 5 6 4 7 3 8 2 9 1 1 0 0 1 0 9 1 1 8
Industry Co de
N u m
b e r
0
4000
8000
12000
16000
1 10 19 28 37 46 55 64 73 82 91 100 109 118
Industry Code
P a te
, , , 45 66
, , .
2 21
.
- ( , 20-30
) ,

, , , 116, 117 Health
& Wellness SOU
- .
B2B ,
, ,
,
.6)
, , (IPC C)
, “
, B2C , ”
.
6)
, .
22 ()

(co-occurrence) 2 .

1990
2000 ()
- ,




- 1990 2000
(co-occurrence matrix)
, ,

2 23
(peer review) .
< 2-4> 28
.
(%)
c06f 4 18 246
c07h 322 1859 470
c07k 570 1310 134
c07m
3 13 400
c11d 270 702 145
c12h 8 9 208
c12m 95 298 191
c12n , -- 824 2707 223
c12p
431 1311 191
c12q , 314 1707 410
c12s 3 27 575
c13d 6 14 125
c13k , , , 3 8 100
c14b , , 2 4 150
c14c , , 8 15 100
c23c , , 457 1082 121
c30b 101 226 104
3629 11776
c05d
c11d Biocide
c12h
c12p
, Low-k , HDP-CDP
, , , ,
,
, C
, , , B2C
.
.
28 ,
,
(< 2-5> ).
- 10
2015 .
- , 15
, 7
.
26 ()
B2C Bio
1 4 5 5 14 0 1 0 15
2 5 5 3 13 1 1 0 15
3 5 5 3 13 1 1 0 15
4 (DDS) 5 5 3 13 1 1 0 15
5 5 4 4 13 0 1 0 14
6 5 5 2 12 1 1 0 14
7 4 5 3 12 1 1 0 14
8 4 5 3 12 1 1 0 14
9 4 4 4 12 1 1 0 14
10 3 5 4 12 0 1 0 13
11 4 5 3 12 0 0 1 13
12 3 5 4 12 0 0 1 13
13 4 4 3 11 1 1 0 13
14 3 4 4 11 0 1 0 12
15 LED 4 5 3 12 0 0 0 12
16 LOC(Lab-on-a-chip) 3 4 4 11 0 1 0 12
17 3 4 3 10 0 1 0 11
18 Bioreactor 3 5 2 10 0 1 0 11
19 2 5 3 10 0 0 0 10
20 Bio-remediation 3 3 2 8 0 1 1 10
21 Biocide 3 0 2 5 1 1 0 7
22 (low-k) 1 2 2 5 0 0 0 5
23 CMP 3 0 0 3 0 0 0 3
24 - - 0 0 0 0 0 0
25 ( ) - - - - - - - -
27 Antisense ( ) - - - - - - - -
28 Apotosis ( ) - - - - - - - -
1) 25
.
3 27
3
3-1> ).
< 3-1>
: IMS World Review, Growth Rates in Local Currency Dollar 2002-2003 Added in
Brackets, 2004(Lundebeck, Financial Presentation, 2004, 2005b, p.41 ).
28 ()
,

.
(< 3-2> ).
< 3-2>
: IMS World Review, Growth Rates in Local Currency Dollar 2002-2003 Added in
Brackets, 2004(Lundebeck, Financial Presentation, 2004, 2005b, p.42 ).
-
3 29
,
.
,
.
1.7 (< 3-1> ).
- , ,
,
.
, , (
).
30 ()
1995 2001
3.4 8.5
20.2 33.4
8.6 10.9
9.8 29.7
60.1 113.7
122.7 168.2
144.7 198.4
13.7 18.8
0.0 0.0
, 0.0 0.2
6.3 7.0
16.8 21.9
0.0 0.3
, , , 2004.
p.82 -5 ) .
, ,
3 31
, , , , .
-
.
,
.


.
2.
772 17% ,
13% (< 3-1> ).
CNS 1
58% (< 3-3> ).
32 ()
< 3-4> CNS
( : $M)
Dollar 2002-2003 Added in Brackets, 2004((Lundebeck,
Annual Report 4, 2005a, p.103 ).
Pfizer, GSK, Eli
Lilly, Johnson & Johnson, Sanofi-aventis (< 3-4> ).
: Wood Mackenzie, Therapeutic Area Review in 2004, 2005, p.2.
Ei Lilly
3 33
2004 620 , 2004~
2009 4.1% 2004 758
.
.
& Johnson), (Novartis), (AstraZeneca),
- - 2,250 , 1,200 ,
720 , 240 , 300
.
(Asta Medica),
(American Biogenetic sciences), (NeuroSearch),
Biosciences( ), (Bayer), Neo-
Therapeutics(), , Bristol-Myers-Squibb(
), Akzo Nobel(), Diatide(
34 ()
.
, 2008 60 , ,
(Medtech Insight,
2004), .
Collins (+ + )
2001 65 , 2010 147
(Ben Collins and Christine
Hollidge, 2003).
, 2008 5 .
- 1.4 , 3.3
(Datamonitor, 2001).

3 35
< 3-5>
.
- ,
(Moon, L. et al., 2003).
.
CNS 3% 27%
.
(< 3-5> ).
: IMS World Review, Growth Rates in Local Currency Dollar
2002-2003 Added in Brackets, 2004(Lundebeck, Annual
Report 4, 2005a, p.105 ).
36 ()
.
Tacrine) Novartis Exelon Pfizer-Eisai
Aricept Tacrine
(< 3-2> ).
< 3-2>
Drug Active compound
Reminyl galantamine Johnson & Johnson 298 78
Ebixa
/Axura
memantine Lundbeck/Merz 87 269
: IMS World Review, Growth Rates in Local Currency Dollar 2002-2003 Added
in Brackets, 2004(Lundebeck, Annual Report 4, 2005a, p.104 ).
Janssen Galanthamine Takeda TAK-147
Phase 3 .

, (Ampakine), (Cortex Phar-
maceuticals) NIH ,
.
3 37
.
CNS 12%, 2003
93 (IMS World Review, 2004) .
1
80%, 2 20%,
2 (< 3-6> ).
- 1 80%
, Novartis Tegretol (carbamazepine),
Abbott Depakote/Valcote(sodium valproate), Pfizer
Dilantin (phenytoin) .
- 2 Pfizer Neurontin(gabapentin),
GSK Lamictal(lamotrigine), UCB Keppra(levetiracetam),
Johnson & Johnson Topamax(topiramate), Novartis
- 2 1 7
.
- Pfizer, Johnson & Johnson, Abbott, GSK, Novartis
75% .
38 ()
(‘03-7~’04.6)
New Drugs Blance Genericisation of Epilepsy Marker,
2004(available at http://www.imshealth.com) ).
growth rate; CAGR) 2008 40
(< 3-7> ).
- Pfizer Neurontin 2002 20 , 2003
27 , GSK Lamictal 2003 10
, UCB Keppra
2 , 2002
3 , 2003 4 .
3 39
< 3-7>
: IMS Therapy Forecaster, 2004(IMS Global Insight, Therapies and
Disease: New Drugs Blance Genericisation of Epilepsy Marker, 2004
(available at http://www.imshealth.com) ).
.
, Gabapentin 1 2300 .
- Pfizer neurontin
Lyrica(pregabalin) , 2004
(neuropathic pain), (post-herpetic
40 ()
.
Phase III .
,

,
.
.
CNS 3%,
9% , 22
(IMS World Review, 2004) .
31%,
41%, 28%.
18.47 (2000)
20.45 (2001) 10.7% , 2010
51.61 .
3 41

/ ,
43% .
21%(2010)
.
levodopa) .

-
.
4 43
, ( )
( ) 2
73.8(< 4-1> ) , ,
2 3,138 (< 4-2> ).
- ,

.
( : )
1
() 123.5
2 3.8 71.0 76.7
3 34.2 35.9 32.5
4 23.8 35.6 24.2
5 22.3 30.7
16.7
: , , 5 , : 2001,
, 79, 2003, p.58, < 1> .
44 ()
( : )


1,977
291,51
2,970
91,83
8,384
12,920,15
9,642
386,00
8,710
15,970,24
1,682
: , , 5 , : 2001,
, 79, 2003, p.65, 6 .
,
(< 4-3> ).
- , 10 2
,
.
-
.
4 45
< 4-3> ( 1,000)
( : )
4.0 5.7 6.5 8.4
4.8 5.9 6.1 9.3
3.2 5.6 6.8 7.5

3.4 5.1 5.3 6.7
5.9 8.1 11.4 15.5
: , “ ”, (, ,
, , , 2004.
p.114 < -44> ) .
.
- (, ,
)
.
- ,
.
.
2008 5
.
phase) , later acute phasem
.
(lipid-lowering drug) .
- OECD 12(,
, , , , , , ,
, , , )
ACE , ,
serum lipid reducer (< 4-1> ).
- statin OECD
.
Expenditure for Cardiovascular Disease and Stroke: A Study of 12
OECD Countries”, OECD HEALTH WORKING PAPERS, 2003, p.52,
8-1 .
- 2008 3.3
70% .
NMDA
.
Pfizer CP 101, 606(troxoprodil)
(< 4-4> ).
48 ()
129.4 , 14.1%
.
Calcium chelator DP -b99 Free radical scavengers -Antioxidants
Ebselen Tirilazad
Growth factors Fibroblast Growth Factor(bFGF)
Leukocyte adhesion inhibitor Anti-ICAM antibody(Enlimomab) Hu23F2G
Nitric oxide inhibitor Lubeluzole
Opioid antagonists Naloxone Nalmefene
Sodium channel blockers Fosphenytoin Lubeluzole 619C89
Potassium channel blockers BMS204352 Mechanism unknown or uncertain
Piracetam Lubeluzole
4 49
.
.
- CP101,606(2005), Maxipost(2005), UK279,276(2006), Argatroban(2007),
Sipatrigine(2007), NXY059(2008) .
,

.
() .
3.
NMDA

.
- 10
2003 .
- ,
50 ()
.

,
,
.

.
- , ( )
,
,

.

.


4 51
-
( )
.
-
.
- ,
.
-
,
.
-
.
-
, NMDA
- ,

.
5 53

, 2 3138
,
.
,

.
, .

, ,
.
54 ()
.
NMDA

.
(Memantine) FDA
,
.
, ( )


.
,
.

5 55

.
1. , , , , “
,” , 6(3),
2003, pp.373-390.
2. , , “-
,” , 8(2), 2005, pp.863-887.
3. ,
, , 2005
4. , ( , , ):
, , 2005
5. , , , , “
,”
, 2004, pp.174-191.
, 2004.
, 2005.
, , 2004.
9. ,
: (TRM) (KM) ,
58 ()
, 2004.
10. ,
, , , 2005.
11. , , 5 , : 2001,
, 79, 2003, pp.55-65.
12. Ben Collins and Christine Hollidge, "Antithrombotiv Drug
Market," Nature Reviews Drug Discovery, 2(1), 2003, p.11-12
13. Butler, T.L., Kassed, C.A. and Pennypacker, K.R., "Signal
Transduction and Neurosurvival in Experimental Models of
Brain Injury," Brain Research Bulletin, 59(5), 2003, pp.331-359.
14. Datamonitor, Drugs, Devices and Procedures of Tomorrow 2001:
Stroke, 2001.
12 OECD Countries,” OECD HEALTH WORKING PAPERS,
2003
16. IMS Global Insights, Therapies and Disease: New Drugs Balance
Genericisation of Epilepsy Market, 2004.
17. Johnson, Daniel K.N., "The OECD Technology Concordance
(OTC), Patents by Industry of Manufacturer and Sector of
USE", OECD STI Working Paper, 2002.
18. Kim, W., Jang, P., Woo, M., Han, I., Piao, H., Lee, K., Lee, H.,
Toh, J. and Kim, H., "A New Anti-inflammatory Agent
59
Nitric Oxide Synthase(iNOS) Gene Expression in Activated
Microglia," Neuropharmacology, 47, 2004, pp.243-252.
19. Lee, J., Cho, J., Kim, H., Lim, J., Oh, Y., Nam, W., Chun, J.
and Kim, W., "Augmented Cerebral Ischemic Injury by
Activated Macrophages/Microglia after Lipopolysaccharide
20. Lundbeck, Financial Presentation, 2004.
21. Lundbeck, Annual Report 4, 2005a.
22. Lundbeck, Financial Presentation, 2005b.
23. Medtech Insight, U.S. Markets for Stroke Management Products,
LLC, 2004.
24. Moon, L., et al., "Stroke Care in OECD Countries: A
Comparison of Treatment, Costs and Outcomes in 17
Countries,, OECD Health Working Papers, 5, 2003.
25. NISTEP, ,
, 2003 , NO. 82.,
2003.
26. Piao, H., Jin, S., Chun, H., Lee, J. and Kim, W.,
"Neuroprotective Effect of Wogonin: Potential Roles of
Inflammatory Cytokines," Archives of Pharmacal Research. 27,
2004, pp.930-936.
60 ()
Social Change, 71, 2004, pp.287-303.
28. Yoon, B. and Park, Y., “A Systematic Approach for Identifying
Technology Opportunities: Keyword-based Morphology Analysis,”
Technological Forecasting & Social Change, 72, 2005, pp.145-160.